Conference on Chemoprevention of Prostate Cancer

描述（由申请人提供）：年度前列腺癌化学预防国际会议及其出版的论文集作为领先的同行评审泌尿学杂志的同行评审CME补充，包括旨在满足社区泌尿科医生和肿瘤学家需求的继续医学教育（CME）计划。 年度会议和持久的教育期刊出版物都将关注与医学界最相关的前沿数据，并促进基础和临床研究最活跃的人在这个有前途的领域中推进和交流信息。 基于第一次会议的教育出版物是专门设计的，通过在该领域领先的同行评审医学杂志《泌尿学杂志》上发表，对尽可能广泛的医学受众有用。 该节目由Ian M.汤普森，医学博士，德克萨斯州圣安东尼奥德克萨斯大学健康科学中心泌尿科教授兼主任。 汤普森博士是公认的领导者和贡献者，促进对前列腺癌治疗和研究新方法的理解，特别是在化学预防领域。 第一次会议计划于2002年3月6日至8日在德克萨斯州的圣安东尼奥举行，为期三天，由20至22名化学预防剂评价和开发方面的临床领导人参加。 随后的会议将轮流在圣安东尼奥和弗吉尼亚州姆克林举行。 该方案的具体目标如下： 回顾和评估前列腺癌化学预防基础和临床研究的最新数据和专家临床观点。 通过发表共识白色论文，向泌尿科医生、肿瘤科医生和其他治疗前列腺癌患者和从事前列腺癌研究的临床医生传播相关性对齐的关键点。 提供一个关于前列腺癌治疗中化学预防的信息平台，供医生使用，提供持续的医疗和患者教育，以领先的同行评审医学期刊上年度会议论文集的形式。

DESCRIPTION (provided by applicant): The annual International Conference on Chemoprevention of Prostate Cancer and its published proceedings as a peer-reviewed CME supplement to a leading peer-reviewed urology journal comprise a continuing medical education (CME) program designed to serve the needs of community-based urologists and oncologists. Both the annual conference and the enduring educational journal publications will focus on the cutting-edge data most relevant to the medical community, and facilitate advancing and communicating information on this promising field from those most active in basic and clinical research. The educational publication based on the first meeting is specifically designed to be useful to the broadest possible medical audience by its publication in the leading peer-reviewed medical journal in the field, The Journal of Urology. The program is directed by Ian M. Thompson, M.D., Professor and Chief, Division of Urology at The University of Texas Health Science Center in San Antonio, Texas. Dr. Thompson is a recognized leader and contributor to advancing understanding of new approaches to prostate cancer treatment and research, in particular in the area chemoprevention. The first meeting, planned for March 6-8, 2002, will be a three-day expert conference of 20-22 clinical leaders in the evaluation and development of chemopreventive agents in San Antonio, Texas. Subsequent meetings will alternate between San Antonio and McLean, Virginia. The specific objectives of the program are as follows: Review and assess recent data and expert clinical perspectives on basic and clinical research on chemoprevention of prostate cancer. Disseminate, through publication of consensus white papers, key points of alignment of relevance to urologists, oncologists and other clinicians treating prostate cancer patients and engaged in prostate cancer research. Provide a platform of information on chemoprevention in prostate cancer therapy that will be utilized by physicians providing ongoing medical and patient education, in the form of the annual published proceedings of the conference in leading peer-reviewed medical journals.